Physician profile
Peter Crosson
NPI 1952481095
$2,745.01
in general payments reported to CMS, 2019-2025
15 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $206 · 2021: $348 · 2022: $255 · 2023: $219 · 2024: $24.09 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $974.14 | 2019-2022 | |
| Pfizer INC. | $315.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.65 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $209.30 | 2019-2025 | Breztri |
| Lilly USA, LLC | $169.58 | 2019-2025 | |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Abbvie INC. | $121.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.71 | 2022 | |
| Merck Sharp & Dohme LLC | $110.73 | 2019 | |
| Cequr Corporation | $109.69 | 2023 | Cequr Simplicity |
| Novo Nordisk INC | $83.04 | 2019-2024 | |
| Glaxosmithkline, LLC. | $61.66 | 2019 | |
| Allergan, INC. | $25.15 | 2019 | |
| Abbott Laboratories | $24.50 | 2022 | |
| Scilex Pharmaceuticals INC. | $21.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Crosson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.